Dr. Jedd D. Wolchok

Dr. Jedd D. Wolchok, MD, PhD, is an internationally acclaimed medical oncologist and physician-scientist, renowned for his groundbreaking contributions to the field of cancer immunotherapy. He is the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and holds the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center. Dr. Wolchok earned his MD and PhD from New York University, followed by residency training in internal medicine and a fellowship in medical oncology at Memorial Sloan Kettering. Board-certified in internal medicine and medical oncology, he is widely recognized for his leadership in advancing immunotherapy approaches, particularly in melanoma.

Dr. Wolchok has been instrumental in the development and clinical validation of immune checkpoint inhibitors, including pivotal work on anti-CTLA-4 and anti-PD-1 therapies that have transformed the treatment landscape for metastatic melanoma and other solid tumors. His research has focused on understanding the mechanisms of immune response and resistance to immunotherapy, leading to innovative combination strategies and personalized treatment regimens. A prolific investigator, he has authored more than 300 peer-reviewed publications and has played a key role in national and international clinical trials that have defined new standards of care in oncology.

Beyond his scientific and clinical achievements, Dr. Wolchok is a passionate educator and mentor who has guided countless trainees in oncology and translational research. He serves on numerous editorial boards and advisory panels, and has held leadership positions within the American Association for Cancer Research, the Society for Immunotherapy of Cancer, and the American Society of Clinical Oncology. Through his unwavering commitment to scientific discovery, patient-centered care, and academic leadership, Dr. Wolchok continues to shape the future of cancer immunotherapy worldwide.